Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
FAIL · Does not pass the screen
7.70 USD
Screen close, 2026-09-21 · not a live quote Last reviewed 15 days ago
Screened 2026-09-21 · the tape above runs as of 13:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 7.70 against the desk's fair-value range, base estimate 14.50, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price7.70 USD
Fair value14.50
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Accumulation4.45+73.0% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Precigen, Inc. holds its Accumulation at $7.70. Elevated stress, defensive posture warranted, held for 23 days.
As held on the ledger · 2026-09-21
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 23 days
Price at the screen
$7.70
Valuation
N/A trailing · -33.80 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.02
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
63.21%
Below 33%
Interest-bearing debt is 63.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
1.61%
Below 33%
Cash held in interest-bearing accounts and securities is 1.6% of assets, under the one-third limit.
Pass
Receivables
21.96%
Below 49%
Money owed to the company is 22.0% of assets, under the 49% limit.
Pass
Revenue purity
33.20%
Below 5%
33.2% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Precigen,'s business is in a permissible area, but its interest-bearing debt is about 63% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 88.3% margin of safety to the base estimate.
Third-party analyst targets: 2 covering, consensus None. The average target sits +88% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Gene therapy hopes collide with zero profits
Picture a lab racing to turn gene edits into medicines for cancer and infections. Precigen shows eye watering revenue growth near 1634 percent yet still posts a zero profit margin and return on equity of minus 1145 percent. The opportunity rating sits at none despite the apparent margin of safety to fair value.
The business stays locked in early clinical work with no proven moat. Forward earnings sit negative at 22.5 times and just two analysts offer any view at all. Ethical checks clear but the numbers reveal a company that burns cash faster than it can prove its platforms work.
Risks centre on trial failures, dilution and the classic biotech trap where big top line growth never turns into sustainable earnings. The market price already reflects that uncertainty.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PGEN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Accumulation$7.70+7.1%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 14% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 152%. Our forward projection puts the odds of a 10% gain over the next month near 41%. The street (2 analysts) rates it buy, with a mean price target of $12. Insiders have been net sellers over the past quarter.
2026-09-09Accumulation$7.19+45.3%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 45.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 14% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 152%. Our forward projection puts the odds of a 10% gain over the next month near 41%. The street (2 analysts) rates it buy, with a mean price target of $12. Insiders have been net sellers over the past quarter.
2026-08-08Accumulation$4.95+11.2%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 11.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 14% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 152%. Our forward projection puts the odds of a 10% gain over the next month near 41%. The street (2 analysts) rates it buy, with a mean price target of $12.
2026-07-18Accumulation$4.45+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 14% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 152%. Our forward projection puts the odds of a 10% gain over the next month near 41%. The street (2 analysts) rates it buy, with a mean price target of $12.
2026-07-03Accumulation$4.45+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$4.45Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
